Novartis India launches Pluvicto for PSMA-positive metastatic prostate cancer EP News Bureau Jun 15, 2026 Radioligand therapy approved for eligible patients with PSMA-positive prostate cancer in India
Novartis signs deal with iTheranostics to develop, commercialise compounds targeting FAP EP News Bureau Mar 30, 2021 Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic…
